1
|
Li H, Hua D, Qu Q, Cao H, Feng Z, Liu N, Huang J, Zhang L. Oral Immunization with Recombinant Saccharomyces cerevisiae Expressing Viral Capsid Protein 2 of Infectious Bursal Disease Virus Induces Unique Specific Antibodies and Protective Immunity. Vaccines (Basel) 2023; 11:1849. [PMID: 38140252 PMCID: PMC10747824 DOI: 10.3390/vaccines11121849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 12/09/2023] [Accepted: 12/13/2023] [Indexed: 12/24/2023] Open
Abstract
Infectious bursal disease (IBD), as a highly infectious immunosuppressive disease, causes severe economic losses in the poultry industry worldwide. Saccharomyces cerevisiae is an appealing vehicle used in oral vaccine formulations to safely and effectively deliver heterologous antigens. It can elicit systemic and mucosal responses. This study aims to explore the potential as oral an vaccine for S. cerevisiae expressing the capsid protein VP2 of IBDV. We constructed the recombinant S. cerevisiae, demonstrated that VP2 was displayed on the cell surface and had high immunoreactivity. By using the live ST1814G/Aga2-VP2 strain to immunize the mice, the results showed that recombinant S. cerevisiae significantly increased specific IgG and sIgA antibody titers, indicating the potential efficacy of vaccine-induced protection. These results suggested that the VP2 protein-expressing recombinant S. cerevisiae strain was a promising candidate oral subunit vaccine to prevent IBDV infection.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jinhai Huang
- School of Life Sciences, Tianjin University, Tianjin 300072, China; (H.L.); (D.H.); (Q.Q.); (H.C.); (Z.F.); (N.L.)
| | - Lei Zhang
- School of Life Sciences, Tianjin University, Tianjin 300072, China; (H.L.); (D.H.); (Q.Q.); (H.C.); (Z.F.); (N.L.)
| |
Collapse
|
2
|
Lucero MS, Chimeno Zoth S, Jaton J, Gravisaco MJ, Pinto S, Richetta M, Berinstein A, Gómez E. Oral Immunization With Plant-Based Vaccine Induces a Protective Response Against Infectious Bursal Disease. FRONTIERS IN PLANT SCIENCE 2021; 12:741469. [PMID: 34868126 PMCID: PMC8636702 DOI: 10.3389/fpls.2021.741469] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 10/18/2021] [Indexed: 06/13/2023]
Abstract
Infectious bursal disease virus (IBDV) is the etiological agent of an immunosuppressive and highly contagious disease that affects young birds causing important economic losses in the poultry industry worldwide. We have previously developed a plant-based vaccine candidate for infectious bursal disease (IBD) that is able to protect against infection with IBDV when administered through intramuscular (im) route. Given that oral vaccination is non-invasive and stimulates the immunity of the mucosal gastrointestinal surface, the initial site of contact and entry of IBDV, the aim of this work was to study if our immunogen was also able to elicit a protective immune response when orally administered. We demonstrated that 85% of the animals that received two oral doses of the vaccine formulation and all animals that were orally boosted after an im prime scheme developed virus neutralizing antibodies and were protected against IBDV infection, evidenced by the bursa/body weight (BB) ratio, absence of T-cell infiltration, and low viral load in bursa. Although mild to moderate bursal damage was observed in some of these animals, these lesions were not as severe as the ones observed in challenged control groups, which also presented signs of acute inflammation, bursal atrophy, T-cell infiltration, and absence of viral clearance. These results show that two immunizations with our recombinant immunogen are able to induce a specific and protective immune response in chicken against IBDV when orally administered in a prime/boost scheme or when the oral boost follows an im prime scheme. In conclusion, our oral plant-based vaccine candidate could represent a viable alternative to conventional vaccines and is of great interest to the poultry industry.
Collapse
Affiliation(s)
- María Soledad Lucero
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Silvina Chimeno Zoth
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Juan Jaton
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - María José Gravisaco
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Silvina Pinto
- Cátedra de Patología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Matías Richetta
- Gerencia de Gestión Estratégica de Procesos Complementarios, Centro de Investigación en Ciencias Veterinarias y Agronómicas, INTA, Buenos Aires, Argentina
| | - Analía Berinstein
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| | - Evangelina Gómez
- Laboratorio de Inmunología y Vacunas Aviares, Instituto de Agrobiotecnología y Biología Molecular, INTA-CONICET, Buenos Aires, Argentina
| |
Collapse
|
3
|
Marusic C, Drissi Touzani C, Bortolami A, Donini M, Zanardello C, Lico C, Rage E, Fellahi S, El Houadfi M, Terregino C, Baschieri S. The expression in plants of an engineered VP2 protein of Infectious Bursal Disease Virus induces formation of structurally heterogeneous particles that protect from a very virulent viral strain. PLoS One 2021; 16:e0247134. [PMID: 33592038 PMCID: PMC7886152 DOI: 10.1371/journal.pone.0247134] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Accepted: 02/01/2021] [Indexed: 11/18/2022] Open
Abstract
Infectious Bursal Disease Virus (IBDV), the etiological agent of Gumboro disease, causes mortality and immunosuppression in chickens and major losses to poultry industry worldwide. The IBDV major capsid protein VP2 is considered the best candidate for the production of novel subunit vaccines. This structural protein contains the major conformational epitopes responsible for the induction of IBDV neutralizing antibodies in chickens and has been demonstrated able to form supramolecular structures in yeast and insect cells. The aim of this study was to express an engineered version of the VP2 protein (His-pVP2) to verify its ability to self-assemble into virus-like particles in plants. The recombinant VP2 was transiently expressed by agroinfiltration in Nicotiana benthamiana and transmission electron microscopy of sucrose density gradient fractions revealed the presence of a mixed population of differently shaped particles ranging from spherical capsids, with a diameter between ~25 and ~70 nm, to tubular structures, with variable length (from 100 to 400 nm). The recombinant VP2-based particles when used for the intramuscular immunization of specific-pathogen-free chicks resulted able to induce the production of anti-IBDV specific antibodies at titers comparable to those induced by a commercial vaccine. Moreover, all the immunized birds survived to the challenge with a Moroccan very virulent IBDV strain with no major histomorphological alterations of the Bursa of Fabricius, similarly to what obtained with the commercial inactivated vaccine.
Collapse
Affiliation(s)
- Carla Marusic
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Charifa Drissi Touzani
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomy and Veterinary Institute Hassan II, Rabat, Morocco
| | - Alessio Bortolami
- Specialized Virology and Experimental Research Department Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Marcello Donini
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Claudia Zanardello
- Diagnostic Services, Histopathology, Parasitology Department, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Chiara Lico
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Emile Rage
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Siham Fellahi
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomy and Veterinary Institute Hassan II, Rabat, Morocco
| | - Mohammed El Houadfi
- Avian Pathology Unit, Pathology and Veterinary Public Health Department, Agronomy and Veterinary Institute Hassan II, Rabat, Morocco
| | - Calogero Terregino
- Specialized Virology and Experimental Research Department Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Selene Baschieri
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| |
Collapse
|
4
|
Li G, Kuang H, Guo H, Cai L, Chu D, Wang X, Hu J, Rong J. Development of a recombinant VP2 vaccine for the prevention of novel variant strains of infectious bursal disease virus. Avian Pathol 2020; 49:557-571. [PMID: 32658552 DOI: 10.1080/03079457.2020.1791314] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Since 2017, novel variant strains of infectious bursal disease virus (nvIBDV) have been detected in China, while the current vaccines on the market against very virulent IBDV have limited protection against this subtype virus. In this context, a strain of the virus has been isolated, and sequencing alignment and bird regression experiments showed that the virus was IBDV, belonging to the nvIBDV subtype (and named IBDV FJ-1812). Furthermore, the Escherichia coli expression system was used to successfully express soluble nvIBDV rVP2, which is specifically recognized by an anti-IBDV standard serum and anti-nvIBDV positive serum, and could be assembled into 14 - 17 nm virus-like particles. Based on the purified nvIBDV rVP2, we developed an IBDV FJ-1812 VP2 VLP vaccine at a laboratory scale to evaluate protection by this vaccine; in addition, we also prepared an IBDV JZ 3/02 VP2 subunit vaccine targeting very virulent IBDV and evaluated its cross-protection against nvIBDV. Results of bird experiments showed that the nvIBDV rVP2 vaccine could induce high titres of specific antibodies, completely protect the bursa of Fabricius from viral infection, and provide 100% immune protection to SPF and Ross 308 broiler chickens. Furthermore, the IBDV JZ 3/02 VP2 subunit vaccine targeting very virulent IBDV could provide 60% protection for SPF chickens and 80% protection for Ross 308 broiler chickens. This report provides important technical supports for the prevention and control of nvIBDV in the future.
Collapse
Affiliation(s)
- Guopan Li
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China
| | - Hongyan Kuang
- The First Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China
| | - Huaxiong Guo
- Department of Pathology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China
| | - Lianshen Cai
- State Key Laboratory of Animal Genetic Engineering Vaccine, Qingdao Yebio Biological Engineering Co., Ltd., Qingdao, People's Republic of China
| | - Dianfeng Chu
- State Key Laboratory of Animal Genetic Engineering Vaccine, Qingdao Yebio Biological Engineering Co., Ltd., Qingdao, People's Republic of China
| | - Xi Wang
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China
| | - Jixiong Hu
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China
| | - Jun Rong
- College of Life Science, Yangtze University, Jingzhou, People's Republic of China.,State Key Laboratory of Animal Genetic Engineering Vaccine, Qingdao Yebio Biological Engineering Co., Ltd., Qingdao, People's Republic of China
| |
Collapse
|
5
|
Hayden CA, Hung CY, Zhang H, Negron A, Esquerra R, Ostroff G, Abraham A, Lopez AG, Gonzales JE, Howard JA. Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever. J Infect Dis 2020; 220:615-623. [PMID: 31184702 DOI: 10.1093/infdis/jiz196] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Accepted: 04/18/2019] [Indexed: 02/01/2023] Open
Abstract
Coccidioides is the causative agent of San Joaquin Valley fever, a fungal disease prevalent in the semiarid regions of the Americas. Efforts to develop a fungal vaccine over the last 2 decades were unsuccessful. A candidate antigen, Antigen 2 (Ag2), is notoriously difficult to express in Escherichia coli, and this study sought to accumulate the antigen at high levels in maize. Transformed maize lines accumulated recombinant Ag2 at levels >1 g/kg. Mice immunized with this antigen and challenged with live Coccidioides arthroconidia showed a reduction in the fungal load when Ag2 derived from either E. coli or maize was loaded into glucan chitin particles. A fusion of Ag2 to dendritic cell carrier peptide (DCpep) induced a T-helper type 17 response in the spleen when orally delivered, indicative of a protective immune response. The maize production platform and the glucan chitin particle adjuvant system show promise for development of a Coccidioides vaccine, but further testing is needed to fully assess the optimal method of administration.
Collapse
Affiliation(s)
- Celine A Hayden
- Applied Biotechnology Institute, San Luis Obispo, California
| | - Chiung-Yu Hung
- Department of Biology, University of Texas, San Antonio, Worcester
| | - Hao Zhang
- Department of Biology, University of Texas, San Antonio, Worcester
| | - Austin Negron
- Department of Biology, University of Texas, San Antonio, Worcester
| | - Raymond Esquerra
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California
| | - Gary Ostroff
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester
| | - Ambily Abraham
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester
| | - Alejandro Gabriel Lopez
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California
| | | | - John A Howard
- Applied Biotechnology Institute, San Luis Obispo, California
| |
Collapse
|
6
|
Current state-of-the-art in the use of plants for the production of recombinant vaccines against infectious bursal disease virus. Appl Microbiol Biotechnol 2020; 104:2287-2296. [PMID: 31980920 DOI: 10.1007/s00253-020-10397-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 01/14/2020] [Accepted: 01/19/2020] [Indexed: 12/11/2022]
Abstract
Infectious bursal disease is a widely spread threatening contagious viral infection of chickens that induces major damages to the Bursa of Fabricius and leads to severe immunosuppression in young birds causing significant economic losses for poultry farming. The etiological agent is the infectious bursal disease virus (IBDV), a non-enveloped virus belonging the family of Birnaviridae. At present, the treatment against the spread of this virus is represented by vaccination schedules mainly based on inactivated or live-attenuated viruses. However, these conventional vaccines present several drawbacks such as insufficient protection against very virulent strains and the impossibility to differentiate vaccinated animals from infected ones. To overcome these limitations, in the last years, several studies have explored the potentiality of recombinant subunit vaccines to provide an effective protection against IBDV infection. In this review, we will give an overview of these novel types of vaccines with special emphasis on current state-of-the-art in the use of plants as "biofactories" (plant molecular farming). In fact, plants have been thoroughly and successfully characterized as heterologous expression systems for the production of recombinant proteins for different applications showing several advantages compared with traditional expression systems (Escherichia coli, yeasts and insect cells) such as absence of animal pathogens in the production process, improved product quality and safety, reduction of manufacturing costs, and simplified scale-up.
Collapse
|
7
|
Hayden CA, Landrock D, Hung CY, Ostroff G, Fake GM, Walker JH, Kier A, Howard JA. Co-Administration of Injected and Oral Vaccine Candidates Elicits Improved Immune Responses over Either Route Alone. Vaccines (Basel) 2020; 8:E37. [PMID: 31973150 PMCID: PMC7157212 DOI: 10.3390/vaccines8010037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/15/2020] [Accepted: 01/16/2020] [Indexed: 12/22/2022] Open
Abstract
Infectious diseases continue to be a significant cause of morbidity and mortality, and although efficacious vaccines are available for many diseases, some parenteral vaccines elicit little or no mucosal antibodies which can be a significant problem since mucosal tissue is the point of entry for 90% of pathogens. In order to provide protection for both serum and mucosal areas, we have tested a combinatorial approach of both parenteral and oral administration of antigens for diseases caused by a viral pathogen, Hepatitis B, and a fungal pathogen, Coccidioides. We demonstrate that co-administration by the parenteral and oral routes is a useful tool to increase the overall immune response. This can include achieving an immune response in tissues that are not elicited when using only one route of administration, providing a higher level of response that can lead to fewer required doses or possibly providing a better response for individuals that are considered poor or non-responders.
Collapse
Affiliation(s)
- Celine A. Hayden
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA; (C.A.H.); (G.M.F.)
| | - Danilo Landrock
- Department of Veterinary Pathobiology, College of Veterinary Medicine, Texas A & M University, College Station, TX 77843, USA; (D.L.); (A.K.)
| | - Chiung Yu Hung
- Department of Biology, University of Texas San Antonio, One UTSA Circle, San Antonio, TX 78249, USA;
| | - Gary Ostroff
- Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation St. Biotech 2, Suite 113, Worcester, MA 01605, USA;
| | - Gina M. Fake
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA; (C.A.H.); (G.M.F.)
| | - John H. Walker
- Department of Statistics, California Polytechnic State University, San Luis Obispo, CA 93407, USA;
| | - Ann Kier
- Department of Veterinary Pathobiology, College of Veterinary Medicine, Texas A & M University, College Station, TX 77843, USA; (D.L.); (A.K.)
| | - John A. Howard
- Applied Biotechnology Institute, Cal Poly Tech Park, San Luis Obispo, CA 93407, USA; (C.A.H.); (G.M.F.)
| |
Collapse
|
8
|
Rage E, Drissi Touzani C, Marusic C, Lico C, Göbel T, Bortolami A, Bonfante F, Salzano AM, Scaloni A, Fellahi S, El Houadfi M, Donini M, Baschieri S. Functional characterization of a plant-produced infectious bursal disease virus antigen fused to the constant region of avian IgY immunoglobulins. Appl Microbiol Biotechnol 2019; 103:7491-7504. [PMID: 31332484 DOI: 10.1007/s00253-019-09992-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 06/13/2019] [Accepted: 06/16/2019] [Indexed: 01/16/2023]
Abstract
Infectious bursal disease virus (IBDV) is the cause of an economically important highly contagious disease of poultry, and vaccines are regarded as the most beneficial interventions for its prevention. In this study, plants were used to produce a recombinant chimeric IBDV antigen for the formulation of an innovative subunit vaccine. The fusion protein (PD-FcY) was designed to combine the immunodominant projection domain (PD) of the viral structural protein VP2 with the constant region of avian IgY (FcY), which was selected to enhance antigen uptake by avian immune cells. The gene construct encoding the fusion protein was transiently expressed in Nicotiana benthamiana plants and an extraction/purification protocol was set up, allowing to reduce the contamination by undesired plant compounds/proteins. Mass spectrometry analysis of the purified protein revealed that the glycosylation pattern of the FcY portion was similar to that observed in native IgY, while in vitro assays demonstrated the ability of PD-FcY to bind to the avian immunoglobulin receptor CHIR-AB1. Preliminary immunization studies proved that PD-FcY was able to induce the production of protective anti-IBDV-VP2 antibodies in chickens. In conclusion, the proposed fusion strategy holds promises for the development of innovative low-cost subunit vaccines for the prevention of avian viral diseases.
Collapse
Affiliation(s)
- Emile Rage
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Charifa Drissi Touzani
- Unité de Pathologie Aviaire, Département de Pathologie et Santé Publique Vétérinaire, IAV Hassan II, Rabat, Morocco
| | - Carla Marusic
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Chiara Lico
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| | - Thomas Göbel
- Department of Veterinary Sciences, LMU Munich, München, Germany
| | - Alessio Bortolami
- Division of Comparative Biomedical Science, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Francesco Bonfante
- Division of Comparative Biomedical Science, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Anna Maria Salzano
- Proteomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, Napoli, Italy
| | - Andrea Scaloni
- Proteomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, Napoli, Italy
| | - Siham Fellahi
- Unité de Pathologie Aviaire, Département de Pathologie et Santé Publique Vétérinaire, IAV Hassan II, Rabat, Morocco
| | - Mohammed El Houadfi
- Unité de Pathologie Aviaire, Département de Pathologie et Santé Publique Vétérinaire, IAV Hassan II, Rabat, Morocco
| | - Marcello Donini
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy.
| | - Selene Baschieri
- Laboratory of Biotechnology, ENEA Casaccia Research Center, Rome, Italy
| |
Collapse
|
9
|
Dey S, Pathak DC, Ramamurthy N, Maity HK, Chellappa MM. Infectious bursal disease virus in chickens: prevalence, impact, and management strategies. VETERINARY MEDICINE-RESEARCH AND REPORTS 2019; 10:85-97. [PMID: 31497527 PMCID: PMC6689097 DOI: 10.2147/vmrr.s185159] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 06/16/2019] [Indexed: 01/03/2023]
Abstract
Infectious bursal disease (IBD), also known as Gumboro disease, is a highly contagious, immunosuppressive disease of young chickens. Although first observed about 60 years ago, to date, the disease is responsible for major economic losses in the poultry industry worldwide. IBD virus (IBDV), a double-stranded RNA virus, exists as two serotypes with only serotype 1 causing the disease in young chickens. The virus infects the bursa of Fabricius of particularly the actively dividing and differentiating lymphocytes of the B-cells lineage of immature chickens, resulting in morbidity, mortality, and immunosuppression. Immunosuppression enhances the susceptibility of chickens to other infections and interferes with vaccination against other diseases. Immunization is the most important measure to control IBD; however, rampant usage of live vaccines has resulted in the evolution of new strains. Although the immunosuppression caused by IBDV is more directed toward the B lymphocytes, the protective immunity in birds depends on inducement of both humoral and cell-mediated immune responses. The interference with the inactivated vaccine induced maternally derived antibodies in young chicks has become a hurdle in controlling the disease, thus necessitating the development of newer vaccines with improved efficacy. The present review illustrates the overall dynamics of the virus and the disease, and the recent developments in the field of virus diagnosis and vaccine research.
Collapse
Affiliation(s)
- Sohini Dey
- Recombinant DNA Lab, Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| | - Dinesh C Pathak
- Recombinant DNA Lab, Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| | - Narayan Ramamurthy
- Recombinant DNA Lab, Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| | - Hemanta Kumar Maity
- Recombinant DNA Lab, Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| | - Madhan Mohan Chellappa
- Recombinant DNA Lab, Division of Veterinary Biotechnology, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| |
Collapse
|
10
|
Liu L, Zhang W, Song Y, Wang W, Zhang Y, Wang T, Li K, Pan Q, Qi X, Gao Y, Gao L, Liu C, Zhang Y, Wang Y, He G, Wang X, Cui H. Recombinant Lactococcus lactis co-expressing OmpH of an M cell-targeting ligand and IBDV-VP2 protein provide immunological protection in chickens. Vaccine 2017; 36:729-735. [PMID: 29289381 DOI: 10.1016/j.vaccine.2017.12.027] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 11/22/2017] [Accepted: 12/11/2017] [Indexed: 12/20/2022]
Abstract
Infectious bursal disease virus (IBDV) is a highly contagious disease that results in enormous economic losses in the global poultry sector. Lactic acid bacteria are an appealing vehicle for the safe and effective delivery of heterologous protein antigens. Oral administration of the commensal bacterium Lactococcus lactis expressing recombinant fusion proteins has been used to elicit mucosal and systemic immune responses. In this study, a Lactococcus lactis NZ3900 strain co-expressing the outer membrane protein (Omp) H of the microfold (M) cell-targeting ligand and the viral capsid protein (VP)2 antigen of IBDV was genetically engineered, and its immunopotentiating capacity as an oral and injected vaccine in chickens was evaluated. Western blotting analysis demonstrated that VP2-OmpH was expressed in the cytoplasm of cells and had high immunoreactivity. An in vivo study showed that in the absence of any adjuvant, the recombinant L. lactis VP2-OmpH strain stimulated the immune response and protected against very virulent IBDV challenge in 100% and 80% of chickens immunized by injection and oral administration, respectively. Moreover, the antiviral neutralizing antibody titers induced by injection administration were higher than those induced by oral administration. Mucosal secretory IgA titers induced by oral administration were higher than those induced by injection administration. These results suggested that the recombinant L. lactis VP2-OmpH strain is a promising candidate vaccine to prevent IBDV infection.
Collapse
Affiliation(s)
- Linlin Liu
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Wang Zhang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
| | - Yuxin Song
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
| | - Wenqian Wang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Yuan Zhang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
| | - Tingting Wang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Kai Li
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Qing Pan
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Xiaole Qi
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Yulong Gao
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Li Gao
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Changjun Liu
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Yanping Zhang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Yongqiang Wang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Gaoming He
- College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
| | - Xiaomei Wang
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| | - Hongyu Cui
- State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, China.
| |
Collapse
|
11
|
A concise review of poultry vaccination and future implementation of plant-based vaccines. WORLD POULTRY SCI J 2017. [DOI: 10.1017/s0043933917000484] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
The case for plant-made veterinary immunotherapeutics. Biotechnol Adv 2016; 34:597-604. [PMID: 26875776 DOI: 10.1016/j.biotechadv.2016.02.007] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 01/14/2016] [Accepted: 02/11/2016] [Indexed: 12/11/2022]
Abstract
The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.
Collapse
|
13
|
Alkie TN, Rautenschlein S. Infectious bursal disease virus in poultry: current status and future prospects. VETERINARY MEDICINE-RESEARCH AND REPORTS 2016; 7:9-18. [PMID: 30050833 PMCID: PMC6055793 DOI: 10.2147/vmrr.s68905] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Infectious bursal disease virus (IBDV) affects immature B lymphocytes of the bursa of Fabricius and may cause significant immunosuppression. It continues to be a leading cause of economic losses in the poultry industry. IBDV, having a segmented double-stranded RNA genome, is prone to genetic variation. Therefore, IBDV isolates with different genotypic and phenotypic diversity exist. Understanding these features of the virus and the mechanisms of protective immunity elicited thereof is necessary for developing vaccines with improved efficacy. In this review, we highlighted the pattern of virus evolution and new developments in prophylactic strategies, mainly the development of new generation vaccines, which will continue to be of interest for research as well as field application in the future.
Collapse
Affiliation(s)
- Tamiru Negash Alkie
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Canada
| | - Silke Rautenschlein
- Clinic for Poultry, University of Veterinary Medicine Hannover, Hannover, Germany,
| |
Collapse
|
14
|
Lee HJ, Kim JY, Kye SJ, Seul HJ, Jung SC, Choi KS. Efficient self-assembly and protective efficacy of infectious bursal disease virus-like particles by a recombinant baculovirus co-expressing precursor polyprotein and VP4. Virol J 2015; 12:177. [PMID: 26502988 PMCID: PMC4621879 DOI: 10.1186/s12985-015-0403-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Accepted: 10/14/2015] [Indexed: 12/17/2022] Open
Abstract
Background Virus-like particle (VLP) technology is considered one of the most promising approaches in animal vaccines, due to the intrinsic immunogenic properties as well as high safety profile of VLPs. In this study, we developed a VLP vaccine against infectious bursal disease virus (IBDV), which causes morbidity and mortality in chickens, by expressing a baculovirus in insect cells. Methods To improve the self-proteolytic processing of precursor polyprotein (PP), we constructed a recombinant baculovirus transfer vector that co-expresses PP and the VP4 protease gene of IBDV. Results Expression and VLP assembly of recombinant proteins and antigenicity of the VLP were examined by Western blotting, ELISA, and transmission electron microscopy. In animal experiments, vaccination with the recombinant VLP induced strong and uniform humoral immunity and provided complete protection against challenge with very virulent (vv) IBDV in SPF chickens (n = 12). As determined by the bursa of Fabricius (BF)/body weight (B/BW) ratio, the protection against post-challenge bursal atrophy was significantly higher (P < 0.001) in VLP-vaccinated birds than in non-vaccinated controls. Conclusions Since the protective efficacy of the VLP vaccine was comparable to that of a commercially available inactivated vaccine, the recombinant VLP merits further investigation as an alternative means of protection against vvIBD.
Collapse
Affiliation(s)
- Hyun-Jeong Lee
- Avian Disease Division, Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi, 430-757, Republic of Korea.
| | - Ji-Ye Kim
- Avian Disease Division, Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi, 430-757, Republic of Korea.
| | - Soo-Jeong Kye
- Avian Disease Division, Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi, 430-757, Republic of Korea.
| | - Hee-Jung Seul
- Avian Disease Division, Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi, 430-757, Republic of Korea.
| | - Suk-Chan Jung
- Avian Disease Division, Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi, 430-757, Republic of Korea.
| | - Kang-Seuk Choi
- Avian Disease Division, Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi, 430-757, Republic of Korea.
| |
Collapse
|
15
|
Overexpression of recombinant infectious bursal disease virus (IBDV) capsid protein VP2 in the middle silk gland of transgenic silkworm. Transgenic Res 2014; 23:809-16. [PMID: 25106848 DOI: 10.1007/s11248-014-9827-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 07/31/2014] [Indexed: 10/24/2022]
Abstract
Infectious bursal disease virus (IBDV) is the causative agent of a highly contagious disease affecting young chickens and causes serious economic losses to the poultry industry worldwide. Development of subunit vaccine using its major caspid protein, VP2, is one of the promising strategies to protect against IBDV. This study aim to test the feasibility of using silkworm to produce recombinant VP2 protein (rVP2) derived from a very virulent strain of IBDV (vvIBDV). A total of 16 transgenic silkworm lines harboring a codon-optimized VP2 gene driven by the sericin1 promoter were generated and analyzed. The results showed that the rVP2 was synthesized in the middle silk gland of all lines and secreted into their cocoons. The content of rVP2 in the cocoon of each line was ranged from 0.07 to 16.10 % of the total soluble proteins. The rVP2 was purified from 30 g cocoon powders with a yield of 3.33 mg and a purity >90 %. Further analysis indicated that the rVP2 was able to tolerate high temperatures up to 80 °C, and exhibited specific immunogenic activity in mice. To our knowledge, this is the first report of overexpressing rVP2 in the middle silk gland of transgenic silkworm, which demonstrates the capability of silkworm as an efficient tool to produce recombinant immunogens for use in new vaccines against animal diseases.
Collapse
|
16
|
Protective oral vaccination against infectious bursal disease virus using the major viral antigenic protein VP2 produced in Pichia pastoris. PLoS One 2013; 8:e83210. [PMID: 24376665 PMCID: PMC3869785 DOI: 10.1371/journal.pone.0083210] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Accepted: 11/01/2013] [Indexed: 11/19/2022] Open
Abstract
Infectious bursal disease virus (IBDV) causes economically important immunosuppressive disease in young chickens. The self-assembling capsid protein (VP2) from IBDV strain IR01 was expressed in Pichia pastoris resulting in the formation of homomeric, 23-nm infectious bursal disease subviral particles (IBD-SVPs) with a yield of 76 mg/l before and 38 mg/l after purification. Anti-IBDV antibodies were detected in chickens injected with purified IBD-SVPs or fed with either purified IBD-SVPs or inactivated P. pastoris cells containing IBD-VP2 (cell-encapsulated). Challenge studies using the heterologous classical IBDV strain (MB3) showed that intramuscular vaccination with 20 µg purified IBD-SVPs conferred full protection, achieved complete virus clearance and prevented bursal damage and atrophy, compared with only 40% protection, 0-10% virus clearance accompanied by severe atrophy and substantial bursal damage in mock-vaccinated and challenge controls. The commercial IBDV vaccine also conferred full protection and achieved complete virus clearance, albeit with partial bursal atrophy. Oral administration of 500 µg purified IBD-SVPs with and without adjuvant conferred 100% protection but achieved only 60% virus clearance with adjuvant and none without it. Moderate bursal damage was observed in both cases but the inclusion of adjuvant resulted in bursal atrophy similar to that observed with live-attenuated vaccine and parenteral administration of 20 µg purified IBD-SVPs. The oral administration of 250 mg P. pastoris cells containing IBD-VP2 resulted in 100% protection with adjuvant and 60% without, accompanied by moderate bursal damage and atrophy in both groups, whereas 25 mg P. pastoris cells containing IBD-VP2 resulted in 90-100% protection with moderate bursal lesions and severe atrophy. Finally, the oral delivery of 50 µg purified IBD-SVPs achieved 40-60% protection with severe bursal lesions and atrophy. Both oral and parenteral administration of yeast-derived IBD-VP2 can therefore induce a specific and protective immune response against IBDV without affecting the growth rate of chickens.
Collapse
|
17
|
Gómez E, Lucero MS, Chimeno Zoth S, Carballeda JM, Gravisaco MJ, Berinstein A. Transient expression of VP2 in Nicotiana benthamiana and its use as a plant-based vaccine against infectious bursal disease virus. Vaccine 2013; 31:2623-7. [PMID: 23583894 DOI: 10.1016/j.vaccine.2013.03.064] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Revised: 03/06/2013] [Accepted: 03/28/2013] [Indexed: 01/28/2023]
Abstract
Infectious Bursal Disease Virus (IBDV) is the etiological agent of an immunosuppressive and highly contagious disease that affects young birds. This disease causes important economic losses in the poultry industry worldwide. The VP2 protein has been used for the development of subunit vaccines in a variety of heterologous platforms. In this context, the aim of this study was to investigate VP2 expression and immunogenicity using an experimental plant-based vaccine against IBDV. We determined that the agroinfiltration of N. benthamiana leaves allowed the production of VP2 with no apparent change on its conformational epitopes. Chickens intramuscularly immunized in a dose/boost scheme with crude concentrated extracts developed a specific humoral response with viral neutralizing ability. Given these results, it seems plausible for a plant-based vaccine to have a niche in the veterinary field. Thus, plants can be an adequate system of choice to produce immunogens against IBDV.
Collapse
Affiliation(s)
- Evangelina Gómez
- Instituto de Biotecnología, CICVyA, INTA, Castelar, Cc 25 B1712WAA, Buenos Aires, Argentina.
| | | | | | | | | | | |
Collapse
|
18
|
Ito A, Gotanda T, Himeno N, Itchoda N, Tabayashi N, Ike K, Sugimoto C, Matsumura T. Booster responses by oral vaccination with transgenic plants against chicken leucocytozoonosis. Avian Pathol 2013; 42:215-20. [PMID: 23607580 DOI: 10.1080/03079457.2013.779635] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We developed a transgenic potato (TrP/R7) expressing the recombinant R7 (rR7) antigen for use as an oral vaccine to protect against a chicken protozoan disease, chicken leucocytozoonosis. The TrP/R7 potato was produced by Agrobacterium tumefaciens-mediated transformation and regeneration, and the R7 gene insertion into potato chromosomes was confirmed by genomic polymerase chain reaction and Southern hybridization. rR7 antigen expression in TrP/R7 potato was also confirmed by sandwich enzyme-linked immunosorbent assay and western blotting using an antibody against the second-generation schizont of Leucocytozoon caulleryi. A transgenic potato clone with the highest rR7 antigen expression (3 µg rR7 antigen per gram of fresh-weight potato leaves) was selected, cultivated, and used in oral administration experiments to examine its ability to boost immunity. Chickens were immunized with chicken leucocytozoonosis vaccine "Hokken" by injection, and chickens that developed moderate levels of antibody titres were fed with TrP/R7 leaves. Chickens fed with TrP/R7 leaves showed increased antibody responses. In contrast, chickens fed with non-transgenic potato leaves showed a continuous decrease in antibody titres. Furthermore, chickens fed with TrP/R7 potato leaves showed strong resistance against experimental challenge with L. caulleryi infection. This study demonstrates the use of a plant-based oral vaccine to boost immunity against a protozoan disease.
Collapse
Affiliation(s)
- Akira Ito
- Bioproduction Research Institute, National Institute of Advanced Industrial and Science Technology, Sapporo, Hokkaido, Japan
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Miller T, Fanton M, Nickelson S, Mason H, Webb S. Safety and immunogenicity of bacterial and tobacco plant cell line derived recombinant native and mutant Escherichia coli heat-labile toxin in chickens. Avian Pathol 2012; 41:441-9. [PMID: 22928883 DOI: 10.1080/03079457.2012.709606] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The safety and immunogenicity of the mammalian mucosal adjuvants, Escherichia coli wild-type heat-labile holotoxin (LT) and E. coli mutant LT (LTA-K63/LTB), were examined in 1-day-old chicks and 10-day-old to 21-day-old broilers. Biologically active, E. coli recombinant wild-type LT and recombinant LTA-K63/LTB produced in a transgenic Nicotiana tabacum (NT-1) tobacco cell line (SLT102) were tested for safety and antigenicity following various routes of administration. Safety was assessed by clinical signs, body weight gain, gross organ pathology and wet organ weight, and histopathology. Antigenicity was assessed using LT-B-specific serum IgG enzyme-linked immunosorbent assay. Parenteral administration of E. coli recombinant wild-type LT did not have any discernible effect on bird health and was well tolerated at levels up to 400 µg per dose. Recombinant, SLT102-derived mutant LT derived from SLT102 cells retained in vitro ganglioside binding and was safe and antigenic following repeated mucosal administration to birds. The highest systemic LT-B-specific IgG titres were detected in birds that received three on-feed doses of SLT102-derived mutant LT. Among the various SLT102-derived mutant LT preparations tested, whole, wet cells or whole cell lysates were the most antigenic. These results demonstrate for the first time that E. coli-derived recombinant, wild-type LT holotoxin is well tolerated following multiple administrations to young birds at body weight doses previously reported to be enteropathogenic and toxic in mammalian species. Moreover, these data also demonstrate the feasibility of using recombinant wild-type and mutant LT produced in transgenic NT-1 tobacco cells as safe and potent vaccine adjuvants in poultry.
Collapse
Affiliation(s)
- Tim Miller
- Benchmark BioLabs, Inc., Lincoln, NE 68528-1574, USA.
| | | | | | | | | |
Collapse
|
20
|
Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit. PLoS One 2012; 7:e42870. [PMID: 23024743 PMCID: PMC3443089 DOI: 10.1371/journal.pone.0042870] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Accepted: 07/12/2012] [Indexed: 01/09/2023] Open
Abstract
Here we report on vaccination approaches against infectious bursal disease (IBD) of poultry that were performed with complete yeast of the species Kluyveromyces lactis (K. lactis). Employing a genetic system that enables the rapid production of stably transfected recombinant K. lactis, we generated yeast strains that expressed defined quantities of the virus capsid forming protein VP2 of infectious bursal disease virus (IBDV). Both, subcutaneous as well as oral vaccination regiments with the heat-inactivated but otherwise untreated yeast induced IBDV-neutralizing antibodies in mice and chickens. A full protection against a subsequent IBDV infection was achieved by subcutaneous inoculation of only milligram amounts of yeast per chicken. Oral vaccination also generated protection: while mortality was observed in control animals after virus challenge, none of the vaccinees died and ca. one-tenth were protected as indicated by the absence of lesions in the bursa of Fabricius. Recombinant K. lactis was thus indicated as a potent tool for the induction of a protective immune response by different applications. Subcutaneously applied K. lactis that expresses the IBDV VP2 was shown to function as an efficacious anti-IBD subunit vaccine.
Collapse
|
21
|
Müller H, Mundt E, Eterradossi N, Islam MR. Current status of vaccines against infectious bursal disease. Avian Pathol 2012; 41:133-9. [PMID: 22515532 DOI: 10.1080/03079457.2012.661403] [Citation(s) in RCA: 135] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Infectious bursal disease virus (IBDV) is the aetiological agent of the acute and highly contagious infectious bursal disease (IBD) or "Gumboro disease". IBD is one of the economically most important diseases that affects commercially produced chickens worldwide. Along with strict hygiene management of poultry farms, vaccination programmes with inactivated and live attenuated viruses have been used to prevent IBD. Live vaccines show a different degree of attenuation; many of them may cause bursal atrophy and thus immunosuppression with poor immune response to vaccination against other pathogens and an increase in vulnerability to various types of infections as possible consequences. Depending on their intrinsic characteristics or on the vaccination procedures, some of the vaccines may not induce full protection against the very virulent IBDV strains and antigenic variants observed in the last three decades. As chickens are most susceptible to IBDV in their first weeks of life, active immunity to the virus has to be induced early after hatching. However, maternally derived IBDV-specific antibodies may interfere with early vaccination with live vaccines. Thus new technologies and second-generation vaccines including rationally designed and subunit vaccines have been developed. Recently, live viral vector vaccines have been licensed in several countries and are reaching the market. Here, the current status of IBD vaccines is discussed.
Collapse
Affiliation(s)
- Hermann Müller
- Institute for Virology, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 29, Leipzig, Germany.
| | | | | | | |
Collapse
|
22
|
Abstract
During the last two decades, researchers have developed robust systems for recombinant subunit vaccine production in plants. Stably and transiently transformed plants have particular advantages that enable immunization of humans and animals via mucosal delivery. The initial goal to immunize orally by ingestion of plant-derived antigens has proven difficult to attain, although many studies have demonstrated antibody production in both humans and animals, and in a few cases, protection against pathogen challenge. Substantial hurdles for this strategy are low-antigen content in crudely processed plant material and limited antigen stability in the gut. An alternative is intranasal delivery of purified plant-derived antigens expressed with robust viral vectors, especially virus-like particles. The use of pattern recognition receptor agonists as adjuvants for mucosal delivery of plant-derived antigens can substantially enhance serum and mucosal antibody responses. In this chapter, we briefly review the methods for recombinant protein expression in plants, and describe progress with human and animal vaccines that use mucosal delivery routes. We do not attempt to compile a comprehensive list, but focus on studies that progressed to clinical trials or those that showed strong indications of efficacy in animals. Finally, we discuss some regulatory concerns regarding plant-based vaccines.
Collapse
Affiliation(s)
- H S Mason
- Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
| | | |
Collapse
|
23
|
Chen TH, Chen TH, Hu CC, Liao JT, Lee CW, Liao JW, Lin MY, Liu HJ, Wang MY, Lin NS, Hsu YH. Induction of protective immunity in chickens immunized with plant-made chimeric Bamboo mosaic virus particles expressing very virulent Infectious bursal disease virus antigen. Virus Res 2012; 166:109-15. [PMID: 22406128 DOI: 10.1016/j.virusres.2012.02.021] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2011] [Revised: 02/20/2012] [Accepted: 02/22/2012] [Indexed: 11/18/2022]
Abstract
Very virulent Infectious bursal disease virus (vvIBDV) causes a highly contagious disease in young chickens and leads to significant economic loss in the poultry industry. Effective new vaccines are urgently needed. Autonomously replicating plant virus-based vector provides attractive means for producing chimeric virus particles (CVPs) in plants that can be developed into vaccines. In this study, we demonstrate the potential for vaccine development of Bamboo mosaic virus (BaMV) epitope-presentation system, where the antigen from vvIBDV VP2 was fused to the N-terminus of BaMV coat protein. Accordingly, an infections plasmid, pBIBD2, was constructed. Inoculation of the recombinant BaMV clone pBIBD2 enabled the generation of chimeric virus, BIBD2, and stable expression of IBDV VP2 antigen on its coat protein. After intramuscular immunization with BIBD2 CVPs, chickens produced antibodies against IBDV and were protected from vvIBDV (V263/TW strain) challenges. These results corroborate the feasibility of BaMV-based CVP platform in plants for the development and production of vaccines against IBDV.
Collapse
Affiliation(s)
- Tsung-Hsien Chen
- Graduate Institute of Biotechnology, National Chung Hsing University, Taichung 402, Taiwan, ROC
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Lu SW, Wang KC, Liu HJ, Chang CD, Huang HJ, Chang CC. Expression of avian reovirus minor capsid protein in plants. J Virol Methods 2011; 173:287-93. [PMID: 21354211 DOI: 10.1016/j.jviromet.2011.02.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Revised: 09/17/2010] [Accepted: 02/17/2011] [Indexed: 11/27/2022]
Abstract
The minor coat protein of the avian reovirus (ARV), σC, encoded by the S1 genome segment, is one of the major candidates for the development of a subunit vaccine against ARV infection. To develop a plant-based vaccine to immunize poultry against ARV infection, we constructed 4 plant nuclear expression vectors with or without codon modification of the S1 gene, and their expression was driven by a CaMV 35S promoter or rice actin1 promoter. In addition, the expressed σC proteins were targeted subcellularly to cytosol or chloroplasts, respectively. Agrobacterium containing the S1 expression constructs was used to transform tobacco leaf disks, and transformants were selected with kanamycin (100 μg/ml). The integration of the S1 transgene into the tobacco chromosome was confirmed by PCR and Southern blot analysis. Western blot analysis with antiserum against σC was performed to determine the expression of σC protein in transgenic tobacco plants. The highest expression levels of σC protein in the cellular extracts of selected p35S1, pActS1 and p35UmS1 transgenic lines were 0.013%, 0.021% and 0.0013% of the total soluble protein, respectively, but the protein was barely detectable in p35TmS1 transgenic lines. However, the level of σC protein expression was not associated with the level of corresponding RNA transcripts in selected transgenic lines. Taken together, the results suggest that the major limiting factor for the expression of σC protein in plants might be at the post-transcriptional level.
Collapse
MESH Headings
- Antigens, Viral/biosynthesis
- Antigens, Viral/genetics
- Blotting, Southern
- Blotting, Western
- Capsid Proteins/biosynthesis
- Capsid Proteins/genetics
- Genetic Vectors
- Mutagenesis, Insertional
- Orthoreovirus, Avian/genetics
- Plants, Genetically Modified/genetics
- Plants, Genetically Modified/metabolism
- Polymerase Chain Reaction
- Recombinant Proteins/biosynthesis
- Recombinant Proteins/genetics
- Recombination, Genetic
- Rhizobium/genetics
- Nicotiana/genetics
- Nicotiana/metabolism
- Transformation, Genetic
- Viral Vaccines/biosynthesis
- Viral Vaccines/genetics
Collapse
Affiliation(s)
- Shih-Wei Lu
- Institute of Biotechnology, National Cheng Kung University, Tainan 701, Taiwan
| | | | | | | | | | | |
Collapse
|
25
|
Kalthoff D, Giritch A, Geisler K, Bettmann U, Klimyuk V, Hehnen HR, Gleba Y, Beer M. Immunization with plant-expressed hemagglutinin protects chickens from lethal highly pathogenic avian influenza virus H5N1 challenge infection. J Virol 2010; 84:12002-10. [PMID: 20810729 PMCID: PMC2977904 DOI: 10.1128/jvi.00940-10] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2010] [Accepted: 08/19/2010] [Indexed: 01/06/2023] Open
Abstract
Highly pathogenic avian influenza (HPAI) is a striking disease in susceptible poultry, which leads to severe economic losses. Inactivated vaccines are the most widely used vaccines in avian influenza virus (AIV) vaccination programs. However, these vaccines interfere with the serological detection of wild-type AIV infections in immunized populations. The use of vaccines that allow differentiation between infected and vaccinated animals (DIVA strategy) would stop current stamping-out policies. Therefore, novel vaccination strategies are needed to allow improved protection of animals and humans against HPAI virus (HPAIV) infection. The presented study analyzed for the first time the immunogenic capacity of plant-expressed full-length hemagglutinin (rHA0) of HPAIV H5N1 in several vaccine formulations within the highly relevant host species chicken. We were able to express plant-expressed rHA0 at high levels and could show that, when administered with potent adjuvants, it is highly immunogenic and can fully protect chicken against lethal challenge infection. Real-time reverse transcription (RT)-PCR and serological tests demonstrated only marginally increased virus replication in animals vaccinated with plant-derived rHA0 compared to animals immunized with an inactivated reference vaccine. In addition, the use of plant-expressed rHA0 also allowed an easy serological differentiation of vaccinated from AIV-infected animals based on antibodies against the influenza virus NP protein.
Collapse
Affiliation(s)
- Donata Kalthoff
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Anatoli Giritch
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Katharina Geisler
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Ulrike Bettmann
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Victor Klimyuk
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Hans-Robert Hehnen
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Yuri Gleba
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| | - Martin Beer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany, ICON Genetics GmbH, Halle, Germany, Bayer Animal Health GmbH, Monheim, Germany
| |
Collapse
|
26
|
Rybicki EP. Plant-made vaccines for humans and animals. PLANT BIOTECHNOLOGY JOURNAL 2010; 8:620-37. [PMID: 20233333 PMCID: PMC7167690 DOI: 10.1111/j.1467-7652.2010.00507.x] [Citation(s) in RCA: 187] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2009] [Revised: 11/30/2009] [Accepted: 12/02/2009] [Indexed: 05/17/2023]
Abstract
The concept of using plants to produce high-value pharmaceuticals such as vaccines is 20 years old this year and is only now on the brink of realisation as an established technology. The original reliance on transgenic plants has largely given way to transient expression; proofs of concept for human and animal vaccines and of efficacy for animal vaccines have been established; several plant-produced vaccines have been through Phase I clinical trials in humans and more are scheduled; regulatory requirements are more clear than ever, and more facilities exist for manufacture of clinic-grade materials. The original concept of cheap edible vaccines has given way to a realisation that formulated products are required, which may well be injectable. The technology has proven its worth as a means of cheap, easily scalable production of materials: it now needs to find its niche in competition with established technologies. The realised achievements in the field as well as promising new developments will be reviewed, such as rapid-response vaccines for emerging viruses with pandemic potential and bioterror agents.
Collapse
Affiliation(s)
- Edward P Rybicki
- Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, South Africa. ed.rybicki@ uct.ac.za
| |
Collapse
|
27
|
|
28
|
Wu H, Williams K, Singh SR, Scissum-Gunn K, Singh NK, Teresa D, Giambrone JJ. Integrity of a recombinant hemagglutinin protein of an avian influenza virus. Biotechnol Lett 2009; 31:1511-7. [DOI: 10.1007/s10529-009-0047-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2009] [Revised: 05/19/2009] [Accepted: 05/21/2009] [Indexed: 11/24/2022]
|
29
|
Joensuu JJ, Niklander-Teeri V, Brandle JE. Transgenic plants for animal health: plant-made vaccine antigens for animal infectious disease control. PHYTOCHEMISTRY REVIEWS : PROCEEDINGS OF THE PHYTOCHEMICAL SOCIETY OF EUROPE 2008; 7:553-577. [PMID: 32214922 PMCID: PMC7089046 DOI: 10.1007/s11101-008-9088-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/09/2007] [Accepted: 02/05/2008] [Indexed: 05/19/2023]
Abstract
A variety of plant species have been genetically modified to accumulate vaccine antigens for human and animal health and the first vaccine candidates are approaching the market. The regulatory burden for animal vaccines is less than that for human use and this has attracted the attention of researchers and companies, and investment in plant-made vaccines for animal infectious disease control is increasing. The dosage cost of vaccines for animal infectious diseases must be kept to a minimum, especially for non-lethal diseases that diminish animal welfare and growth, so efficient and economic production, storage and delivery are critical for commercialization. It has become clear that transgenic plants are an economic and efficient alternative to fermentation for large-scale production of vaccine antigens. The oral delivery of plant-made vaccines is particularly attractive since the expensive purification step can be avoided further reducing the cost per dose. This review covers the current status of plant-produced vaccines for the prevention of disease in animals and focuses on barriers to the development of such products and methods to overcome them.
Collapse
Affiliation(s)
- J. J. Joensuu
- Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3
| | - V. Niklander-Teeri
- Department of Applied Biology, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland
| | - J. E. Brandle
- Southern Crop Protection and Food Research Centre, Agriculture and Agri-Food Canada, 1391 Sandford Street, London, ON Canada N5V 4T3
| |
Collapse
|
30
|
Abstract
This review examines the challenges of segregating biopharmed crops expressing pharmaceutical or veterinary agents from mainstream crops, particularly those destined for food or feed use. The strategy of using major food crops as production vehicles for the expression of pharmaceutical or veterinary agents is critically analysed in the light of several recent episodes of contamination of the human food chain by non-approved crop varieties. Commercially viable strategies to limit or avoid biopharming intrusion into the human food chain require the more rigorous segregation of food and non-food varieties of the same crop species via a range of either physical or biological methods. Even more secure segregation is possible by the use of non-food crops, non-crop plants or in vitro plant cultures as production platforms for biopharming. Such platforms already under development range from outdoor-grown Nicotiana spp. to glasshouse-grown Arabidopsis, lotus and moss. Amongst the more effective methods for biocontainment are the plastid expression of transgenes, inducible and transient expression systems, and physical containment of plants or cell cultures. In the current atmosphere of heightened concerns over food safety and biosecurity, the future of biopharming may be largely determined by the extent to which the sector is able to maintain public confidence via a more considered approach to containment and security of its plant production systems.
Collapse
Affiliation(s)
- Denis J Murphy
- Biotechnology Unit, Division of Biological Sciences, University of Glamorgan, Treforest, CF37 1DL, UK.
| |
Collapse
|
31
|
Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview. Transgenic Res 2007; 16:315-32. [PMID: 17436059 PMCID: PMC7089296 DOI: 10.1007/s11248-007-9095-x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2007] [Accepted: 03/19/2007] [Indexed: 11/29/2022]
Abstract
During the past two decades, antibodies, antibody derivatives and vaccines have been developed for therapeutic and diagnostic applications in human and veterinary medicine. Numerous species of dicot and monocot plants have been genetically modified to produce antibodies or vaccines, and a number of diverse transformation methods and strategies to enhance the accumulation of the pharmaceutical proteins are now available. Veterinary applications are the specific focus of this article, in particular for pathogenic viruses, bacteria and eukaryotic parasites. We focus on the advantages and remaining challenges of plant-based therapeutic proteins for veterinary applications with emphasis on expression platforms, technologies and economic considerations.
Collapse
Affiliation(s)
- Doreen Manuela Floss
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, Gatersleben, 06466 Germany
| | | | - Udo Conrad
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstrasse 3, Gatersleben, 06466 Germany
| |
Collapse
|
32
|
Rice J, Ainley WM, Shewen P. Plant-made vaccines: biotechnology and immunology in animal health. Anim Health Res Rev 2007; 6:199-209. [PMID: 16583782 DOI: 10.1079/ahr2005110] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AbstractThe use of plants as production systems for vaccine antigens has been actively investigated over the last 15 years. The original research focused on the value of this expression system for oral delivery based on the hypothesis that plant-expressed antigens would be more stable within the digestive tract and would allow for the use of the oral route of administration to stimulate a mucosal immune response. However, while first conceived for utility via the oral route, plant-made antigens have also been studied as classical immunogens delivered via a needle to model animal systems. Antigens have been expressed in a number of whole plant and cell culture systems. Several alternative expression platforms have been developed to increase expression of antigens or to elicit preferred immunological responses. The biotechnological advances in plant expression and the immunological testing of these antigens will be reviewed in this paper focusing primarily on diseases of livestock and companion animals.
Collapse
Affiliation(s)
- J Rice
- Dow AgroSciences, 9330 Zionsville Road, Indianapolis, IN 46268, USA.
| | | | | |
Collapse
|
33
|
Omar AR, Kim CL, Bejo MH, Ideris A. Efficacy of VP2 protein expressed in E. coli for protection against highly virulent infectious bursal disease virus. J Vet Sci 2006; 7:241-7. [PMID: 16871018 PMCID: PMC3242123 DOI: 10.4142/jvs.2006.7.3.241] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The ability of a heat-inactivated whole virus from a highly virulent infectious bursal disease virus (hvIBDV) and VP2 protein from hvIBDV expressed in E. coli provided protection against a hvIBDV challenge in specificpathogen-free (SPF) chickens. Six out of seven chickens that were injected three times with crude VP2 protein developed significant antibody titer against IBDV. However, only four out of the seven chickens survived the hvIBDV challenge. Despite showing low antibody titer profiles, all chickens immunized with the heat-inactivated whole virus also survived the challenged with hvIBDV. However, all of these chickens had bursal atrophy and mild to moderate depletion of lymphocytes. Thus, antibodies raised against IBDV VP2 protein expressed in E. coli and denatured IBDV proteins induced some degree of protection against mortality but not against bursal damage following challenge with hvIBDV.
Collapse
Affiliation(s)
- Abdul Rahman Omar
- Institute of Bioscience, University Putra Malaysia, 43400 UPM Serdang, Selangor Darul Ehsan, Malaysia.
| | | | | | | |
Collapse
|
34
|
Huang LK, Liao SC, Chang CC, Liu HJ. Expression of avian reovirus sigmaC protein in transgenic plants. J Virol Methods 2006; 134:217-22. [PMID: 16488486 DOI: 10.1016/j.jviromet.2006.01.013] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2005] [Revised: 01/12/2006] [Accepted: 01/12/2006] [Indexed: 11/30/2022]
Abstract
Avian reovirus (ARV) structural protein, sigmaC encoded by S1 genome segment, is the prime candidate to become a vaccine against ARV infection. Two plant nuclear expression vectors with expression of sigmaC-encoding gene driven by CaMV 35S promoter and rice actin promoter were constructed, respectively. Agrobacterium containing the S1 expression constructs were used to transform alfalfa, and transformants were selected using hygromysin. The integration of S1 transgene in alfalfa chromosome was confirmed by PCR and histochemical GUS staining. Western blot analysis using antiserum against sigmaC was carried out to determine the expression of sigmaC protein in transgenic alfalfa cells. The highest expression levels of sigmaC protein in the cellular extracts of selected p35S-S1 and pAct1-S1 transgenic alfalfa lines were 0.008% and 0.007% of the total soluble protein, respectively. The transgenic alfalfa cells with expression of sigmaC protein pave the way for the development of edible vaccine.
Collapse
Affiliation(s)
- Liang-Kai Huang
- Institute of Biotechnology, National Cheng Kung University, Tainan 701, Taiwan
| | | | | | | |
Collapse
|